TScan Therapeutics, Inc.
TCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $179 | $133 | $120 | $161 |
| Short-Term Investments | $111 | $59 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $2 | $4 | $4 |
| Total Curr. Assets | $293 | $194 | $124 | $166 |
| Property Plant & Equip (Net) | $72 | $71 | $69 | $17 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $5 | $5 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $7 | $7 | $1 | $0 |
| Total NC Assets | $78 | $78 | $75 | $22 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $371 | $272 | $199 | $188 |
| Liabilities | – | – | – | – |
| Payables | $4 | $2 | $3 | $2 |
| Short-Term Debt | $5 | $7 | $4 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $12 | $10 | $4 | $11 |
| Other Curr. Liab. | $15 | $11 | $7 | $7 |
| Total Curr. Liab. | $36 | $30 | $17 | $21 |
| LT Debt | $93 | $86 | $82 | $4 |
| Deferred Rev, NC | $1 | $6 | $0 | $1 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $94 | $91 | $82 | $6 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $65 | $62 | $53 | $4 |
| Total Liabilities | $130 | $121 | $100 | $27 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$375 | -$248 | -$158 | -$92 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $616 | $398 | $258 | $253 |
| Total Equity | $241 | $151 | $99 | $161 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $371 | $272 | $199 | $188 |
| Net Debt | -$81 | -$41 | -$34 | -$155 |